Marty Lefkowitz

Also affiliated with Novartis (China), Novartis (United States), Pharmac, Tris Pharma (United States)

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction”.

Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction

European Heart Journal(2021)10.1093/eurheartj/ehab499

N/A

4.2DataRank · unranked

154 citations

Pardeep S. Jhund, Inder S. Anand, Hans‐Dirk Düngen, Carolyn S.P. Lam, Marty Lefkowitz +15 more

Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy

JACC Heart Failure(2021)10.1016/j.jchf.2021.01.011

N/A

0DataRank · unranked

43 citations

Brian Claggett, Margaret M. Redfield, Sanjiv J. Shah, Inder S. Anand, Felipe A. Martínez +9 more